MINI LONG - NOVO-NORDISK B | Real-time Bid/Ask 06:07:52 2024-07-11 am EDT | ||
| 17.34 EUR / 17.35 EUR | -0.83% |
|
| Current month | -2.62% | ||
| 1 month | -1.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 17.31 | -1.03% |
| 24-07-10 | 17.49 | +2.28% |
| 24-07-09 | 17.1 | -2.95% |
| 24-07-08 | 17.62 | +0.86% |
| 24-07-05 | 17.47 | +2.34% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 04:44 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA8FBT |
| ISIN | DE000MA8FBT3 |
| Date issued | 2021-08-09 |
| Strike | 330.6 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.81 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.01 € |
| Spread % | 0.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
976.2
DKK
Average target price
953.5
DKK
Spread / Average Target
-2.32%
- Stock Market
- Certificates
- Certificat
